Moderna shares surged Wednesday after the company and Merck reported the first successful Phase 3 trial of a personalized mRNA cancer treatment, a potentially important validation of technology that has been under development for years.
The experimental therapy, called intismeran autogene, was tested in combination with Merck’s blockbuster immunotherapy Keytruda in 1,137 patients with high-risk stage IIB through IV melanoma whose tumors had already been surgically removed.
The goal was not to shrink an existing tumor.
It was to prevent the cancer from coming back.
The study met its primary endpoint of improving recurrence-free survival and also met a key secondary endpoint by reducing the risk that the cancer would spread to distant parts of the body.
No new safety signals emerged.
The companies have not yet released the full Phase 3 data, including the exact magnitude of the benefit, and plan to present detailed results at a medical meeting.
That is an important limitation.
But the trial still represents a major milestone because it is the first positive Phase 3 result for an individualized neoantigen therapy and the first successful late-stage trial of an mRNA-based cancer treatment.
Moderna shares jumped roughly 90% in premarket trading Wednesday, while Merck rose about 7.5%.
The technology works very differently from a conventional vaccine.
Doctors first analyze the genetic mutations inside an individual patient’s tumor. Moderna then manufactures a personalized mRNA treatment designed around those mutations, effectively giving the immune system a customized list of cancer targets to recognize.
That individualized treatment is then administered alongside Keytruda, which helps remove the biological brakes that cancer cells use to hide from the immune system.
The theory is straightforward: Keytruda helps activate the immune system, while the personalized mRNA therapy tells it more precisely what to attack.
Earlier Phase 2 data had already produced encouraging results.
After five years of follow-up, the combination reduced the risk of recurrence or death by 49% compared with Keytruda alone in patients with high-risk stage III or IV melanoma.
Wednesday’s Phase 3 result is more important because it tested the treatment in a much larger group and is designed to support potential regulatory approval.
Merck and Moderna expect to begin discussions with regulators in the coming months.
For Moderna, the financial stakes are enormous.
The company built its global reputation around its COVID-19 vaccine but has been searching for the next major commercial use of its mRNA platform as pandemic-era vaccine revenue declined.
Cancer could become that second act.
For Merck, the timing is equally important.
Keytruda is one of the most valuable medicines in the world, but its key patents begin expiring later this decade. Combining it with a new personalized cancer treatment could extend Merck’s dominance in oncology while creating an entirely new product category.
Analysts have already estimated that the melanoma indication alone could eventually generate billions of dollars in annual sales.
The opportunity could become much larger if the same approach works in other cancers.
Merck and Moderna are already studying the treatment across multiple tumor types, including lung, kidney and bladder cancers.
That is why Wednesday’s result matters beyond melanoma.
The companies have not yet proved that personalized mRNA therapy will work broadly across cancer.
They have, however, now crossed one of the most difficult barriers in drug development: a successful large Phase 3 trial.
The same technology that showed the world how quickly mRNA could be used to build vaccines is now moving toward a very different application.
Instead of making one vaccine for millions of people, Moderna is trying to make a different cancer treatment for each individual patient.
Wednesday’s results suggest that idea may be closer to becoming a commercial reality.
JBizNews Desk | Cambridge, Massachusetts
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.
